within Pharmacolibrary.Drugs.ATC.N;

model N03AX23
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.97,
    Cl             = 5.766666666666667e-05,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.022000000000000002,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N03AX23</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Brivaracetam is an anticonvulsant medication used as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy. It is a high-affinity ligand for synaptic vesicle protein 2A (SV2A) and is approved for use in several countries, including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects (both sexes, ages 18-65) after oral administration.</p><h4>References</h4><ol><li><p> (2024). Comparison Table: Some oral antiseizure medications. <i>The Medical letter on drugs and therapeutics</i> 66(1708) e133–e140. DOI:<a href=\"https://doi.org/10.58347/tml.2024.1708b\">10.58347/tml.2024.1708b</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39073881/\">https://pubmed.ncbi.nlm.nih.gov/39073881</a></p></li><li><p>Jukier, T, et al., &amp; Gross, A (2024). Single intravenous and oral dose pharmacokinetics of the antiseizure medication brivaracetam in healthy cats. <i>Journal of veterinary pharmacology and therapeutics</i> 47(6) 461–468. DOI:<a href=\"https://doi.org/10.1111/jvp.13473\">10.1111/jvp.13473</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39018069/\">https://pubmed.ncbi.nlm.nih.gov/39018069</a></p></li><li><p>Klein, P, &amp; Bourikas, D (2024). Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy. <i>Advances in therapy</i> 41(7) 2682–2699. DOI:<a href=\"https://doi.org/10.1007/s12325-024-02876-z\">10.1007/s12325-024-02876-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38811492/\">https://pubmed.ncbi.nlm.nih.gov/38811492</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N03AX23;
